From licensing to sustainable local manufacturing: what does it really take?
At Nigeria’s 🇳🇬 Health Sector-Wide Joint Annual Review, Medicines Patent Pool showcased its work in Nigeria and joined @UNITAID, @USPGlobalHealth, @Fidsoncares and Codix Bio to discuss how technology enabling policies, quality standards and predictable markets can strengthen local production and access to health products. Drawing on MPP-supported projects in Nigeria, including baloxavir manufacturing and rapid diagnostic tests, five key messages emerged:
🔹 Technology transfer takes time and investment.
Olugbenga Olayeye of @Fidsoncares highlighted the technical and regulatory steps needed to bring medicines to market.
🔹 Partnerships and people matter.
Mary Abulu-Ogangwu of Codix Bio Ltd shared progress in building local manufacturing capacity, while stressing the urgent need for predictable procurement and committed buyers.
🔹 Policy creates opportunity.
@TiwaBraimoh of @MedsPatentPool emphasised how enabling policies can unlock investment and support local manufacturing.
🔹 Quality and skills are essential.
Uchenna Ugwuleke of @USPharmacopeia highlighted the importance of manufacturing readiness, workforce development and sustainable quality systems.
🔹 Markets must make business sense.
Dr. Kelechi Julian Uzor of @UNITAID stressed that competitive pricing, appropriate financing and credible demand are essential for long-term sustainability.
Thank you to Nasir Mohammed of PVAC for moderating and to all our partners for sharing their experiences, and Haliru Ndanusa Yahaya, OON, the Emir of Shonga, for honouring us with his presence.
The takeaway? A licence opens the door, but sustainable access depends on strong partnerships, skilled people, supportive policies and predictable markets.
#GlobalHealth #TechnologyTransfer #LocalManufacturing #AccessToMedicines #Nigeria #GlobalHealth
At Nigeria’s 🇳🇬 Health Sector-Wide Joint Annual Review, Medicines Patent Pool showcased its work in Nigeria and joined @UNITAID, @USPGlobalHealth, @Fidsoncares and Codix Bio to discuss how technology enabling policies, quality standards and predictable markets can strengthen local production and access to health products. Drawing on MPP-supported projects in Nigeria, including baloxavir manufacturing and rapid diagnostic tests, five key messages emerged:
🔹 Technology transfer takes time and investment.
Olugbenga Olayeye of @Fidsoncares highlighted the technical and regulatory steps needed to bring medicines to market.
🔹 Partnerships and people matter.
Mary Abulu-Ogangwu of Codix Bio Ltd shared progress in building local manufacturing capacity, while stressing the urgent need for predictable procurement and committed buyers.
🔹 Policy creates opportunity.
@TiwaBraimoh of @MedsPatentPool emphasised how enabling policies can unlock investment and support local manufacturing.
🔹 Quality and skills are essential.
Uchenna Ugwuleke of @USPharmacopeia highlighted the importance of manufacturing readiness, workforce development and sustainable quality systems.
🔹 Markets must make business sense.
Dr. Kelechi Julian Uzor of @UNITAID stressed that competitive pricing, appropriate financing and credible demand are essential for long-term sustainability.
Thank you to Nasir Mohammed of PVAC for moderating and to all our partners for sharing their experiences, and Haliru Ndanusa Yahaya, OON, the Emir of Shonga, for honouring us with his presence.
The takeaway? A licence opens the door, but sustainable access depends on strong partnerships, skilled people, supportive policies and predictable markets.
#GlobalHealth #TechnologyTransfer #LocalManufacturing #AccessToMedicines #Nigeria #GlobalHealth
0
1
2
102
📢 Call for applications – Expert Advisory Group (EAG) Member (Voluntary and non-remunerated position)
The @MedsPatentPool is inviting applications from experienced professionals to join its Expert Advisory Group (EAG) in a voluntary and non-remunerated capacity.
We are in individuals with experience in the non-governmental sector or communities living with diseases with a focus on non-communicable diseases (NCDs).
🗓️ Application deadline: 30 November 2026
👉 medicinespatentpool.org/rfp-vacancy/ca…
#CallForApplications #ExpertAdvisoryGroup #PublicHealth #NCDs #AccessToMedicines #GlobalHealth #VolunteerOpportunity
The @MedsPatentPool is inviting applications from experienced professionals to join its Expert Advisory Group (EAG) in a voluntary and non-remunerated capacity.
We are in individuals with experience in the non-governmental sector or communities living with diseases with a focus on non-communicable diseases (NCDs).
🗓️ Application deadline: 30 November 2026
👉 medicinespatentpool.org/rfp-vacancy/ca…
#CallForApplications #ExpertAdvisoryGroup #PublicHealth #NCDs #AccessToMedicines #GlobalHealth #VolunteerOpportunity
0
0
0
63
MedicinesPatentPool retweeted
Congratulations to the @AtMIndex on #ATMIndex10!
It is encouraging to see voluntary licensing and technology transfer recognised among the approaches that can help turn innovation into access, and to see the progress of several of MPP’s partners reflected in this year’s Index.
It is encouraging to see voluntary licensing and technology transfer recognised among the approaches that can help turn innovation into access, and to see the progress of several of MPP’s partners reflected in this year’s Index.
NOW ONLINE: The 2026 Access to Medicine Index looks back at two decades of change in how the pharmaceutical industry approaches access to medicine – and how the industry has evolved with it.
Read it here➡️
accesstomedicinefoundation.org/news/pharmaceu…
#ATMIndex10 #access2meds #healthequity #pharma
0
3
3
174
Today, @AtMIndex launches its #ATMIndex10, assessing how 20 of the world's largest pharmaceutical companies are working to improve access to #health products in low- and middle-income countries.
At @MedsPatentPool, we are particularly pleased to see #PublicHealth voluntary ised as an important mechanism for expanding access, alongside #TechnologyTransfer as a means of strengthening manufacturing capacity and supply. The Index highlights how these approaches can support availability, affordability and sustainable supply by enabling quality-assured generic manufacture and competition.
Congratulations to our partners whose efforts are recognised in this year's Index, including @Novartis, @GSK /@ViiVHC and @Roche, and to all companies working to strengthen equitable access through voluntary licensing, technology transfer and other sustainable access approaches.
The findings are another reminder of what partnership can make possible, and of the opportunity to use these approaches more widely to help health innovations reach the people who need them.
Access the 2026 Access to Medicine Index: accesstomedicinefoundation.org/insights-resou…
#AccesstoMedicine #EquitableAccess #HealthEquity
At @MedsPatentPool, we are particularly pleased to see #PublicHealth voluntary ised as an important mechanism for expanding access, alongside #TechnologyTransfer as a means of strengthening manufacturing capacity and supply. The Index highlights how these approaches can support availability, affordability and sustainable supply by enabling quality-assured generic manufacture and competition.
Congratulations to our partners whose efforts are recognised in this year's Index, including @Novartis, @GSK /@ViiVHC and @Roche, and to all companies working to strengthen equitable access through voluntary licensing, technology transfer and other sustainable access approaches.
The findings are another reminder of what partnership can make possible, and of the opportunity to use these approaches more widely to help health innovations reach the people who need them.
Access the 2026 Access to Medicine Index: accesstomedicinefoundation.org/insights-resou…
#AccesstoMedicine #EquitableAccess #HealthEquity
0
1
2
85
🌍🤝 Strengthening #Africa’s capacity to manufacture innovative health technologies!
MPP, @SwiftPharmaInc & South Africa’s @CSIR sign a technology transfer agreement to advance Griffithsin manufacturing in Africa 🧬🏭
💜 Supporting innovation in #STI prevention (including #HIV, #HPV & more) and strengthening manufacturing capacity in LMICs.
👉 Read more: medicinespatentpool.org/news-publicati…
#GlobalHealth #TechnologyTransfer #WomensHealth
MPP, @SwiftPharmaInc & South Africa’s @CSIR sign a technology transfer agreement to advance Griffithsin manufacturing in Africa 🧬🏭
💜 Supporting innovation in #STI prevention (including #HIV, #HPV & more) and strengthening manufacturing capacity in LMICs.
👉 Read more: medicinespatentpool.org/news-publicati…
#GlobalHealth #TechnologyTransfer #WomensHealth
0
1
2
67
What’s the future of PrEP?
A conversation about HIV prevention pipeline trends and access possibilities
Yesterday morning, Lobna Gaayeb, from @MedsPatentPool (MPP), delivered an invited talk at @HIVGlasgow 2026, exploring the evolving landscape of HIV pre-exposure prophylaxis on people acquiring HIV in 2025 – approximately one every 26 seconds – expanding access to highly effective prevention options is urgent. While we have the tools, the challenge is ensuring they reach the people who need them, faster and more equitably.
MPP thanks the conference co-chairs, Alexandra Calmy and Chloe Orkin, and the conference committee for putting this important topic in the spotlight.
#HIVGlasgow #HIVGlasgow2026 #HIVPrevention #PrEP #GlobalHealth
A conversation about HIV prevention pipeline trends and access possibilities
Yesterday morning, Lobna Gaayeb, from @MedsPatentPool (MPP), delivered an invited talk at @HIVGlasgow 2026, exploring the evolving landscape of HIV pre-exposure prophylaxis on people acquiring HIV in 2025 – approximately one every 26 seconds – expanding access to highly effective prevention options is urgent. While we have the tools, the challenge is ensuring they reach the people who need them, faster and more equitably.
MPP thanks the conference co-chairs, Alexandra Calmy and Chloe Orkin, and the conference committee for putting this important topic in the spotlight.
#HIVGlasgow #HIVGlasgow2026 #HIVPrevention #PrEP #GlobalHealth
0
2
2
106
📢 Request for Proposals: Hosting, Maintenance, Support and Development of the MedsPaL Platform
The @MedsPatentPool invites proposals for the hosting, technical maintenance, operational support and continued development of #MedsPaL, its public Medicines Patents and Licences eliable, cost-effective services that maintain platform stability, security, data integrity and continuity, while supporting agreed improvements.
👉 medicinespatentpool.org/rfp-vacancy/re…
🔗 medspal.org
🗓️ Application deadline: 18 December 2026
#RequestforProposals
The @MedsPatentPool invites proposals for the hosting, technical maintenance, operational support and continued development of #MedsPaL, its public Medicines Patents and Licences eliable, cost-effective services that maintain platform stability, security, data integrity and continuity, while supporting agreed improvements.
👉 medicinespatentpool.org/rfp-vacancy/re…
🔗 medspal.org
🗓️ Application deadline: 18 December 2026
#RequestforProposals
0
0
0
71
"It is wonderful to see there is an opportunity to influence more change when community members come together."
These are the words of @BahatiHauleTz from @afrocab_hiv, an NGO that focuses on tackling HIV. She was speaking at a recent webinar jointly held by @MedsPatentPool and n on her membership of MPP's Community Advisory Panel (CAP).
Membership of the CAP means that Bahati can "be a bridge to my people and community," in low- and middle-income countries and being able to influence decisions about access to key essential medicines.
MPP is expanding its Community Advisory Panel (CAP) and invites community representatives living with or affected by cardio-metabolic diseases, cancer, sickle-cell disease, malaria and viral hepatitis to apply.
📅 Apply by 30 November 2026.
🔗 Learn more and apply: medicinespatentpool.org/rfp-vacancy/ca…
🔗 Learn more about the CAP: lnkd.in/eHuTzBir
#VoluntaryLicensing #AccessToMedicines #GlobalHealth #HealthEquity #Innovation #Partnerships #NCDs #Obesity #GLP1basedtherapies #CommunityAdvisoryPanel
These are the words of @BahatiHauleTz from @afrocab_hiv, an NGO that focuses on tackling HIV. She was speaking at a recent webinar jointly held by @MedsPatentPool and n on her membership of MPP's Community Advisory Panel (CAP).
Membership of the CAP means that Bahati can "be a bridge to my people and community," in low- and middle-income countries and being able to influence decisions about access to key essential medicines.
MPP is expanding its Community Advisory Panel (CAP) and invites community representatives living with or affected by cardio-metabolic diseases, cancer, sickle-cell disease, malaria and viral hepatitis to apply.
📅 Apply by 30 November 2026.
🔗 Learn more and apply: medicinespatentpool.org/rfp-vacancy/ca…
🔗 Learn more about the CAP: lnkd.in/eHuTzBir
#VoluntaryLicensing #AccessToMedicines #GlobalHealth #HealthEquity #Innovation #Partnerships #NCDs #Obesity #GLP1basedtherapies #CommunityAdvisoryPanel
1
1
3
106
MedicinesPatentPool retweeted
Access depends not only on whether a medicine is patented, but on how patents and market exclusivities are interpreted across jurisdictions. Growing divergence can shape very different pathways, timelines, to competition and access.
Big thanks to MPP medspal.org
Big thanks to MPP medspal.org
0
1
1
21
🎥 Celebrating 10 years of #MedsPaL with a new tutorial!
As part of MedsPaL’s 10-year anniversary, we are pleased to release Tutorial #4 in our series on how to make the most of the database.
Building on our previous tutorial on advanced filters, discover pop-up information results tables with add/remove columns, easily export or share your search results and use advanced filters for licences. 🌍💊
🔗 Explore MedsPaL: medspal.org
🎉 Read our 10-year anniversary statement: medicinespatentpool.org/news-publicati…
#WorldIPDay #GlobalHealth #AccessToMedicines #HealthInnovation #PublicHealth #OpenAccess
@UNITAID @SwissDevCoop @MofaJapan_en
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) @WIPO @IFPMA @coeff_giving @francediplo
As part of MedsPaL’s 10-year anniversary, we are pleased to release Tutorial #4 in our series on how to make the most of the database.
Building on our previous tutorial on advanced filters, discover pop-up information results tables with add/remove columns, easily export or share your search results and use advanced filters for licences. 🌍💊
🔗 Explore MedsPaL: medspal.org
🎉 Read our 10-year anniversary statement: medicinespatentpool.org/news-publicati…
#WorldIPDay #GlobalHealth #AccessToMedicines #HealthInnovation #PublicHealth #OpenAccess
@UNITAID @SwissDevCoop @MofaJapan_en
Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) @WIPO @IFPMA @coeff_giving @francediplo
0
0
0
84
#HiringNow
🔬 Scientific and Medical Affairs Manager
📍 Mumbai, India 🇮🇳
💡Do you want your scientific judgement to support access to medicines ?
In this role, you will assess candidate medicines, assess clinical evidence, follow innovation pipelines, normative guidance and recommendations that shape which products MPP seeks to license for increased access in low- and middle-income countries.
🗓️ Apply by 13 November 2026
🔗 lnkd.in/edZ5FYj4
🔁 Please share with anyone in your network who would be a great fit. 🙏
#ClinicalProductSpecialist #HIV #GlobalHealthIndia
#ScientificProjectManagement #BusinessDevelopment
🔬 Scientific and Medical Affairs Manager
📍 Mumbai, India 🇮🇳
💡Do you want your scientific judgement to support access to medicines ?
In this role, you will assess candidate medicines, assess clinical evidence, follow innovation pipelines, normative guidance and recommendations that shape which products MPP seeks to license for increased access in low- and middle-income countries.
🗓️ Apply by 13 November 2026
🔗 lnkd.in/edZ5FYj4
🔁 Please share with anyone in your network who would be a great fit. 🙏
#ClinicalProductSpecialist #HIV #GlobalHealthIndia
#ScientificProjectManagement #BusinessDevelopment
0
0
2
151
This morning, @DanaMozaffari, Patent Information Specialist at @MedsPatentPool, presented in the frame on the discussions on the Patents and Health Topic at the 38th session of @WIPO's Standing Committee on the Law of Patents (SCP 38) in Geneva.
His presentation highlighted a sPaL, now covering:
- 217 health products
- 33,801 national patent applications
- 86 licences
- 203 jurisdictions
He also presented recent developments in LAPaL, MPP’s database dedicated to long-acting therapeutics, bringing together clinical, patent, licensing and regulatory information.
Both databases contribute to better transparency and support efforts to expand access to key health products.
🔎 Discover MedsPaL: medspal.org and LAPaL: lnkd.in/eQDfHRXF
#MedsPaL #LAPaL #WIPO #AccessToMedicines #PublicHealth
His presentation highlighted a sPaL, now covering:
- 217 health products
- 33,801 national patent applications
- 86 licences
- 203 jurisdictions
He also presented recent developments in LAPaL, MPP’s database dedicated to long-acting therapeutics, bringing together clinical, patent, licensing and regulatory information.
Both databases contribute to better transparency and support efforts to expand access to key health products.
🔎 Discover MedsPaL: medspal.org and LAPaL: lnkd.in/eQDfHRXF
#MedsPaL #LAPaL #WIPO #AccessToMedicines #PublicHealth
0
1
2
105
💻 JOIN US: @WorldObesity Federation and @MedsPatentPool webinar: Role of communities in access to medicines
🗓️ Date: Thursday 5th November 2026
🕑 Time: 14:00-15:00 CET
🔗 Link: lnkd.in/e_R_GGVW
Meet @BahatiHauleTz from @afrocab_hiv Treatment Access Partnership, a n the HIV space. Bahati is a long-standing member of MPP's Community Advisory Panel (CAP) and we're delighted that she will be participating in a webinar hosted jointly by @MedsPatentPool and the @WorldObesity Federation, to discuss her role on the CAP and her advocacy work in the HIV space.
The CAP ensures that the voices of those living with certain diseases and conditions are properly heard. That's why at the webinar we are announcing our call for applications for a person with lived experience of obesity, hypertension or Type 2 diabetes.
If this sounds like you, then do join us!
#VoluntaryLicensing #AccessToMedicines #GlobalHealth #HealthEquity #Innovation #Partnerships #NCDs #Obesity #GLP1basedtherapies #CommunityAdvisoryPanel
🗓️ Date: Thursday 5th November 2026
🕑 Time: 14:00-15:00 CET
🔗 Link: lnkd.in/e_R_GGVW
Meet @BahatiHauleTz from @afrocab_hiv Treatment Access Partnership, a n the HIV space. Bahati is a long-standing member of MPP's Community Advisory Panel (CAP) and we're delighted that she will be participating in a webinar hosted jointly by @MedsPatentPool and the @WorldObesity Federation, to discuss her role on the CAP and her advocacy work in the HIV space.
The CAP ensures that the voices of those living with certain diseases and conditions are properly heard. That's why at the webinar we are announcing our call for applications for a person with lived experience of obesity, hypertension or Type 2 diabetes.
If this sounds like you, then do join us!
#VoluntaryLicensing #AccessToMedicines #GlobalHealth #HealthEquity #Innovation #Partnerships #NCDs #Obesity #GLP1basedtherapies #CommunityAdvisoryPanel
0
1
1
76
MedicinesPatentPool retweeted
🎂 Congratulations to the @MedsPatentPool on 10 years of MedsPaL!
GARDP has worked with MPP on patent landscape assessments of ceftazidime–avibactam and aztreonam–avibactam, helping inform access strategies, market shaping, affordability and potential generic market entry in low- and middle-income countries.
Peter Beyer, Deputy Executive Director of GARDP, highlights the importance of this work:
“Access to effective antibiotics depends not only on developing new treatments, but also on ensuring they can reach the people who need them. By making patent and licensing information transparent and easily accessible, MedsPaL provides a valuable resource for organisations working to expand access to medicines in low- and middle-income countries.”
#AccessToMedicines #Antibiotics
GARDP has worked with MPP on patent landscape assessments of ceftazidime–avibactam and aztreonam–avibactam, helping inform access strategies, market shaping, affordability and potential generic market entry in low- and middle-income countries.
Peter Beyer, Deputy Executive Director of GARDP, highlights the importance of this work:
“Access to effective antibiotics depends not only on developing new treatments, but also on ensuring they can reach the people who need them. By making patent and licensing information transparent and easily accessible, MedsPaL provides a valuable resource for organisations working to expand access to medicines in low- and middle-income countries.”
#AccessToMedicines #Antibiotics
💡 Access to medicines starts with access to information.
🤝🏽 For the past decade, MedsPaL has helped governments, procurement agencies, manufacturers, researchers and public health organisations navigate complex patent and licensing landscapes by making critical information sier to access.
🌐 Since its launch in 2016, MedsPaL has expanded from around 4,000 patent applications covering three disease areas to a global resource containing information on 217 health products, 33,800 patent applications and 86 public licences across 203 jurisdictions.
🎂 As MedsPaL marks its 10th anniversary, we're proud to reflect on how transparency can support informed decision-making and help advance access to health technologies around the world.
🙏🏽 We're grateful to the many organisations and individuals who have contributed to MedsPaL's development over the past decade, and to our funders and supporters, including @UNITAID, @SwissDevCoop, Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH, the Government of Japan, and @coeff_giving, whose contributions help sustain and strengthen MPP's patent information activities.
🗞️ Read our anniversary statement and discover how @DrDuneton (Unitaid), @JayasreeKIyer (@AtMIndex), @Peter_Beyer (Global Antibiotic R&D Partnership (@gardp_amr), Harm Veerkamp (@IDA_Foundation) Nikola Trifunovic (i+solutions), Jithu Krishnan J (@SunPharma_Live), Viktor Cherniavskyi (@UNDP Global Health Supply Centre), Marion (Amy) Dietterich (@WIPO World Intellectual Property Organization), and @lorenzomoja (@WHO) have used and supported MedsPaL throughout its journey.
🔗 lnkd.in/eX4B4but
Access MedsPaL > medspal.org
#MedsPaL #AccessToMedicines #GlobalHealth #PublicHealth #HealthInnovation
0
1
4
289
💡 Access to medicines starts with access to information.
🤝🏽 For the past decade, MedsPaL has helped governments, procurement agencies, manufacturers, researchers and public health organisations navigate complex patent and licensing landscapes by making critical information sier to access.
🌐 Since its launch in 2016, MedsPaL has expanded from around 4,000 patent applications covering three disease areas to a global resource containing information on 217 health products, 33,800 patent applications and 86 public licences across 203 jurisdictions.
🎂 As MedsPaL marks its 10th anniversary, we're proud to reflect on how transparency can support informed decision-making and help advance access to health technologies around the world.
🙏🏽 We're grateful to the many organisations and individuals who have contributed to MedsPaL's development over the past decade, and to our funders and supporters, including @UNITAID, @SwissDevCoop, Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH, the Government of Japan, and @coeff_giving, whose contributions help sustain and strengthen MPP's patent information activities.
🗞️ Read our anniversary statement and discover how @DrDuneton (Unitaid), @JayasreeKIyer (@AtMIndex), @Peter_Beyer (Global Antibiotic R&D Partnership (@gardp_amr), Harm Veerkamp (@IDA_Foundation) Nikola Trifunovic (i+solutions), Jithu Krishnan J (@SunPharma_Live), Viktor Cherniavskyi (@UNDP Global Health Supply Centre), Marion (Amy) Dietterich (@WIPO World Intellectual Property Organization), and @lorenzomoja (@WHO) have used and supported MedsPaL throughout its journey.
🔗 lnkd.in/eX4B4but
Access MedsPaL > medspal.org
#MedsPaL #AccessToMedicines #GlobalHealth #PublicHealth #HealthInnovation
🤝🏽 For the past decade, MedsPaL has helped governments, procurement agencies, manufacturers, researchers and public health organisations navigate complex patent and licensing landscapes by making critical information sier to access.
🌐 Since its launch in 2016, MedsPaL has expanded from around 4,000 patent applications covering three disease areas to a global resource containing information on 217 health products, 33,800 patent applications and 86 public licences across 203 jurisdictions.
🎂 As MedsPaL marks its 10th anniversary, we're proud to reflect on how transparency can support informed decision-making and help advance access to health technologies around the world.
🙏🏽 We're grateful to the many organisations and individuals who have contributed to MedsPaL's development over the past decade, and to our funders and supporters, including @UNITAID, @SwissDevCoop, Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH, the Government of Japan, and @coeff_giving, whose contributions help sustain and strengthen MPP's patent information activities.
🗞️ Read our anniversary statement and discover how @DrDuneton (Unitaid), @JayasreeKIyer (@AtMIndex), @Peter_Beyer (Global Antibiotic R&D Partnership (@gardp_amr), Harm Veerkamp (@IDA_Foundation) Nikola Trifunovic (i+solutions), Jithu Krishnan J (@SunPharma_Live), Viktor Cherniavskyi (@UNDP Global Health Supply Centre), Marion (Amy) Dietterich (@WIPO World Intellectual Property Organization), and @lorenzomoja (@WHO) have used and supported MedsPaL throughout its journey.
🔗 lnkd.in/eX4B4but
Access MedsPaL > medspal.org
#MedsPaL #AccessToMedicines #GlobalHealth #PublicHealth #HealthInnovation
1
1
3
384
📊 What does the long-acting landscape look like today?
LAPaL brings together 125 curated entries across three key categories:
🔹 42 technology platforms & delivery systems
🔹 29 compounds
🔹 56 long-acting formulations & regimens
And the landscape is expanding well beyond a single tHIV and contraception to malaria, diabetes, pain management, oncology and more, LAPaL helps users explore where long-acting innovation is taking place.
🌍 A growing landscape of long-acting technologies: lapal.ch
👉 If you want to subscribe to the newsletter: lapal.ch/news
LAPaL receives funding from @UNITAID @coeff_giving and The National Institutes of Health through the Long-Acting Extended Release Antiretroviral Research Resource Program (@Long_Acting_HIV) The platform is curated in partnership with the @LivUni's Centre of Excellence for Long-acting Therapeutics (@CELTLiverpool)
#LAPaL #LongActingTherapeutics #HealthInnovation #GlobalHealth #AccessToMedicines
LAPaL brings together 125 curated entries across three key categories:
🔹 42 technology platforms & delivery systems
🔹 29 compounds
🔹 56 long-acting formulations & regimens
And the landscape is expanding well beyond a single tHIV and contraception to malaria, diabetes, pain management, oncology and more, LAPaL helps users explore where long-acting innovation is taking place.
🌍 A growing landscape of long-acting technologies: lapal.ch
👉 If you want to subscribe to the newsletter: lapal.ch/news
LAPaL receives funding from @UNITAID @coeff_giving and The National Institutes of Health through the Long-Acting Extended Release Antiretroviral Research Resource Program (@Long_Acting_HIV) The platform is curated in partnership with the @LivUni's Centre of Excellence for Long-acting Therapeutics (@CELTLiverpool)
#LAPaL #LongActingTherapeutics #HealthInnovation #GlobalHealth #AccessToMedicines
0
0
3
95
Yesterday, members of MPP’s Expert Advisory Group (EAG) came together in Geneva 🇨🇭 and online 💻 for their annual meeting.
💡 The EAG plays an important role in MPP’s governance. It advises MPP’s Governance Board and Executive Director on licence negotiations and assesses onditions of proposed agreements meet MPP’s key requirements. Its members bring expertise spanning intellectual property, public health, clinical expertise, R&D, regulatory affairs and pharmaceutical business development.
🤝 This breadth of independent expertise is invaluable as MPP navigates an increasingly diverse portfolio of medicines and health technologies.
📄 Discussions yesterday covered recent Board decisions; MPP’s business development and in-licensing strategy; the latest developments in the mRNA Technology Transfer Programme 2.0; and policy and market access case studies.
🙏 A big thank you to our EAG Chair Peter Beyer and to all EAG members who joined us in Geneva and online for sharing their time, expertise and perspectives.
Their contributions help ensure that MPP’s work continues to benefit from rigorous, diverse and independent expert advice.
👉 Learn more about MPP’s EAG: medicinespatentpool.org/who-we-are/gov…
#GlobalHealth #AccessToMedicines
💡 The EAG plays an important role in MPP’s governance. It advises MPP’s Governance Board and Executive Director on licence negotiations and assesses onditions of proposed agreements meet MPP’s key requirements. Its members bring expertise spanning intellectual property, public health, clinical expertise, R&D, regulatory affairs and pharmaceutical business development.
🤝 This breadth of independent expertise is invaluable as MPP navigates an increasingly diverse portfolio of medicines and health technologies.
📄 Discussions yesterday covered recent Board decisions; MPP’s business development and in-licensing strategy; the latest developments in the mRNA Technology Transfer Programme 2.0; and policy and market access case studies.
🙏 A big thank you to our EAG Chair Peter Beyer and to all EAG members who joined us in Geneva and online for sharing their time, expertise and perspectives.
Their contributions help ensure that MPP’s work continues to benefit from rigorous, diverse and independent expert advice.
👉 Learn more about MPP’s EAG: medicinespatentpool.org/who-we-are/gov…
#GlobalHealth #AccessToMedicines
0
0
2
124